Evidence map›Paper›PMID 33444637›Full record

ArticleNeuropharmacology2021

Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors.

Matthew Hein, Guangchen Ji, Dalton Tidwell, Preston D'Souza, Takaki Kiritoshi, Vadim Yakhnitsa, Edita Navratilova, Frank Porreca, Volker Neugebauer

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Matthew HeinDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Guangchen JiDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Dalton TidwellDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Preston D'SouzaDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Takaki KiritoshiDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Vadim YakhnitsaDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Edita NavratilovaDepartment of Pharmacology, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA.
Frank PorrecaDepartment of Pharmacology, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA.
Volker NeugebauerDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Electronic address: volker.neugebauer@ttuhsc.edu.
Texas Tech University · USUniversity of Arizona · US

Funding

PAIN, NOCICEPTION, AND THE AMYGDALAR01NS038261 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Volker Neugebauer, Igor Ponomarev · 1999 to 2026
$8.7M
Stress-induced descending facilitation from amygdala kappa opioid receptors in functional painR01NS106902 · NINDS · UNIVERSITY OF ARIZONA · PI NEUGEBAUER, VOLKER, PORRECA, FRANK · 2018 to 2022
$2.7M
Cortical opioid dysfunction in chronic painR01DA041809 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK, WANG, ZAIJIE JIM · 2016 to 2020
$2.7M
Pronociceptive and antinociceptive opioid mechanisms in the central nucleus of the amygdalaR01NS109255 · NINDS · UNIVERSITY OF ARIZONA · PI JI, GUANGCHEN, NAVRATILOVA, EDITA · 2019 to 2023
$2.5M
NIDA NIH HHS R01 DA041809NINDS NIH HHS R01 NS038261NINDS NIH HHS R01 NS106902NINDS NIH HHS R01 NS109255
6 · The paper itself

Abstract

Recent evidence suggests that kappa opioid receptors (KOR) in limbic brain regions such as the amygdala contribute to pain conditions, but underlying mechanisms remain to be determined. The amygdala is an important player in averse-affective aspects of pain and pain modulation. The central nucleus (CeA) serves output functions through projection neurons that include corticotropin releasing factor (CRF) expressing neurons. The CeA is also rich in KOR. Here we tested the novel hypothesis that KOR activation in the CeA generates pain-like behaviors through a mechanism that involves inhibition of synaptic inhibition (disinhibition) of CRF neurons. Intra-CeA administration of a KOR agonist (U-69,593) increased vocalizations of naïve rats to noxious stimuli, and induced anxiety-like behaviors in the open field test (OFT) and avoidance in the conditioned place preference test, without affecting mechanosensory thresholds. Optogenetic silencing of CeA-CRF neurons blocked the facilitatory effects of systemically applied U-69,593 in naïve rats. Patch-clamp recordings of CRF neurons in rat brain slices found that U-69,593 decreased feedforward inhibitory transmission evoked by optogenetic stimulation of parabrachial afferents, but had no effect on monosynaptic excitatory transmission. U-69,593 decreased frequency, but not amplitude, of inhibitory synaptic currents, suggesting a presynaptic action. Multiphoton imaging of CeA-CRF neurons in rat brain slices showed that U-69,593 increased calcium signals evoked by electrical stimulation of presumed parabrachial input. This study shows for the first time that KOR activation increases activity of amygdala CRF neurons through synaptic disinhibition, resulting in averse-affective pain-like behaviors. Blocking KOR receptors may therefore represent a novel therapeutic strategy.

Indexed as

AmygdalaAnimalsBenzeneacetamidesCorticotropin-Releasing HormoneMalePainPain MeasurementPyrrolidinesRatsRats, TransgenicRats, WistarReceptors, Opioid, kappaStereotaxic TechniquesVocalization, AnimalBenzeneacetamidesCorticotropin-Releasing HormonePyrrolidinesReceptors, Opioid, kappaU 69593AmygdalaBehaviorCorticotropin-releasing factorKappa opioid receptorPainPatch clamp

Identifiers

PMID33444637
PMCPMC7887082
OpenAlexW3119150740

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.